The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment patterns of knee osteoarthritis patients in Korea

  • Park, Ha-Rim (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Cho, Soo-Kyung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases) ;
  • Im, Seul Gi (Department of Statistics, Kyungpook National University) ;
  • Jung, Sun-Young (Chung-Ang University Collage of Pharmacy) ;
  • Kim, Dalho (Department of Statistics, Kyungpook National University) ;
  • Jang, Eun Jin (Department of Information Statistics, Andong National University) ;
  • Sung, Yoon-Kyoung (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases)
  • Received : 2017.08.31
  • Accepted : 2017.10.16
  • Published : 2019.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To evaluate the treatment patterns of knee osteoarthritis (OA) patients in South Korea. Methods: Using the Korean nationwide claims database, all knee OA patients in Korea during 2014 were identified by the knee OA diagnostic code (M17) or any OA diagnostic code (M15 to M19) in combination with a procedure for a knee X-ray. Patterns of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CSs), analgesics, and symptomatic slow acting drugs for OA (SYSADOA) were analyzed. Prevalence and characteristics of knee OA patients who received a CS intra-articular injection (IAI) were also evaluated. Results: We identified 2,016,516 knee OA patients whose age (mean ± standard deviation) was 63.2 ± 10.8 years. The number of patients with at least one use of NSAIDs, analgesics, CS, and SYSADOA were 82.5%, 32.2%, 8.6%, and 43.4%, respectively. The use of herbal SYSADOAs was 29.7%. For regular users (medication possession ratios ≥ 50%), the use of NSAIDs was substantially decreased (48.8%), while the use of SYSADOA (37.3%) and CS (6.7%) were not significantly changed. The number of CS IAI users among knee OA patients was 0.18%; they were slightly older (64.4 ± 10.9 vs. 63.2 ± 10.8, p < 0.01) and more skewed towards females (75.7% vs. 71.5%, p < 0.01) than patients who had not received CS IAI. Conclusions: In Korea, the use of SYSADOA or CS in knee OA patients was relatively high. Further studies on the effectiveness and the safety of these treatment options for knee OA are needed.

Keywords

Acknowledgement

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HC15C3388).

References

  1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223. https://doi.org/10.1016/S0140-6736(12)61689-4
  2. Nguyen US, Zhang Y, Zhu Y, Niu J, Zhang B, Felson DT. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med 2011;155:725-732. https://doi.org/10.7326/0003-4819-155-11-201112060-00004
  3. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91-97. https://doi.org/10.1136/ard.60.2.91
  4. Kim I, Kim HA, Seo YI, Song YW, Jeong JY, Kim DH. The prevalence of knee osteoarthritis in elderly community residents in Korea. J Korean Med Sci 2010;25:293-298. https://doi.org/10.3346/jkms.2010.25.2.293
  5. Park JH, Hong JY, Han K, et al. Prevalence of symptomatic hip, knee, and spine osteoarthritis nationwide health survey analysis of an elderly Korean population. Medicine (Baltimore) 2017;96:e6372. https://doi.org/10.1097/MD.0000000000006372
  6. Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg 2013;21:571-576.
  7. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-474. https://doi.org/10.1002/acr.21596
  8. National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain); National Institute for Health and Care Excellence (Great Britain); National Collaborating Centre for Chronic Conditions (Great Britain). Osteoarthritis: Care and Management in Adults. London (UK): National Clinical Guideline Centre, 2014.
  9. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363-388. https://doi.org/10.1016/j.joca.2014.01.003
  10. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155. https://doi.org/10.1136/ard.2003.011742
  11. Wilson N, Sanchez-Riera L, Morros R, et al. Drug utilization in patients with OA: a population-based study. Rheumatology (Oxford) 2015;54:860-867. https://doi.org/10.1093/rheumatology/keu403
  12. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.
  13. Park HR, Cho SK, Im SG, Jung SY, Jang EJ, Sung YK. Identification of knee osteoarthritis patients in the claims database. The 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017); 2017 Oct 16-20; Dubai, UAE.
  14. Hartog A, Hougee S, Faber J, et al. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators. Phytomedicine 2008;15:313-320. https://doi.org/10.1016/j.phymed.2007.09.005
  15. Yoo WH, Yoo HG, Park SH, et al. Efficacy and safety of PG201 (Layla(R)) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. Rheumatol Int 2014;34:1369-1378. https://doi.org/10.1007/s00296-014-2964-8
  16. Shin SS, Jin M, Jung HJ, et al. Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford) 2003;42:665-672. https://doi.org/10.1093/rheumatology/keg209
  17. Lee SY, Kwon HK, Lee SM. SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis. Arch Pharm Res 2011;34:1773-1777. https://doi.org/10.1007/s12272-011-1121-0
  18. Lapane KL, Liu SH, Dube CE, Driban JB, McAlindon TE, Eaton CB. Factors associated with the use of hyaluronic acid and corticosteroid injections among patients with radiographically confirmed knee osteoarthritis: a retrospective data analysis. Clin Ther 2017;39:347-358. https://doi.org/10.1016/j.clinthera.2017.01.006
  19. Chae MK, Bang JS, Lee YJ. Patterns of over-the-counter drug use and interactions between over-the-counter drugs and prescription drugs in adults visiting a community pharmacy. Korean J Clin Pharm 2013;23:49-56.
  20. Seo HJ, Sung YK, Choi CB, et al. Prevalence and factors affecting glucosamine use in Korea: a survey-based study. Rheumatol Int 2013;33:1627-1631. https://doi.org/10.1007/s00296-011-2288-x
  21. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808. https://doi.org/10.1056/NEJMoa052771
  22. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75:37-44. https://doi.org/10.1136/annrheumdis-2014-206792
  23. Runhaar J, Rozendaal RM, van Middelkoop M, et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis 2017;76:1862-1869. https://doi.org/10.1136/annrheumdis-2017-211149
  24. da Costa BR, Hari R, Juni P. Intra-articular corticosteroids for osteoarthritis of the knee. JAMA 2016;316:2671-2672. https://doi.org/10.1001/jama.2016.17565

Cited by

  1. Recommended and real-world treatment of knee osteoarthritis in Korea: differences and compromises vol.34, pp.5, 2019, https://doi.org/10.3904/kjim.2019.265
  2. International descriptive study for comparison of treatment patterns in patients with knee osteoarthritis between Korea and Japan using claims data vol.22, pp.11, 2019, https://doi.org/10.1111/1756-185x.13711
  3. Current state of total knee arthroplasty vol.63, pp.8, 2020, https://doi.org/10.5124/jkma.2020.63.8.452
  4. Effect of a Nationwide Real‐Time Drug Utilization Review System on Duplicated Nonsteroidal Antiinflammatory Drug Prescriptions in Korea vol.72, pp.10, 2019, https://doi.org/10.1002/acr.24054
  5. Low prevalence of radiographic hip osteoarthritis and its discordance with hip pain: A nationwide study in Korea vol.21, pp.1, 2021, https://doi.org/10.1111/ggi.14085
  6. Efficacy and safety of celecoxib combined with JOINS in the treatment of degenerative knee osteoarthritis: study protocol of a randomized controlled trial vol.13, 2019, https://doi.org/10.1177/1759720x211024025
  7. Osteoarthritis year in review 2020: epidemiology & therapy vol.29, pp.2, 2021, https://doi.org/10.1016/j.joca.2020.10.007
  8. Diagnosis and Treatment of Rheumatic Diseases Important to the Elderly vol.22, pp.1, 2019, https://doi.org/10.15656/kjcg.2021.22.1.1
  9. Psychometric Properties of the Korean Version of the Patient Knowledge Questionnaire-Osteoarthritis vol.31, pp.1, 2019, https://doi.org/10.1177/10547738211001964